glp-1 receptor agonist brand names America's Poison Centers GLP-1 Medications for Weight Loss
Description
Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity
Accumulated evidence has shown that the RAAS is no longer considered to act just as an endocrine system, but also as a paracrine, autocrine and intracrine system
[DOI] [PubMed] [Google Scholar] 112.Blher M, Aras M, Aronne LJ, et al
doi: 10.1038/s41467-022-28683-0 [DOI] [PMC free article] [PubMed] [Google Scholar] 111
Personalization Through Genetic Insights and Peptide Pathway Mapping The rapid scaling of GLP-1 use has revealed substantial inter-individual variability in treatment response, side effect profiles, and optimal dosing trajectories
PMID: 7883856
